Geneva, 20 May 2014 – The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has published today a new report and recommendations on Hepatitis encouraging a comprehensive approach to fighting this silent epidemic. Titled “Towards a Sustainable, Intersectoral Approach to Viral Hepatitis”, the report is meant to inform the upcoming discussion at the 67th World...
Read moreGeneva, 19 May 2014 – The International Federation of Red Cross and Red Crescent Societies (IFRC) and the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) launch today, during a side event at the 67th World Health Assembly, a global initiative, called ‘4 Healthy Habits’. This innovative partnership will provide Red Cross and Red Crescent...
Read moreResearch-based pharmaceutical industry adds its voice by calling for greater focus on awareness, research and access. • Psoriasis is a chronic, painful, disfiguring and disabling disease affecting 125 million people worldwide for which there is no cure. • Many go undertreated despite treatments options causing avoidable suffering and high rates of psoriasis associated illnesses; and...
Read moreMarch 13, 2014, Moscow — The Association of International Pharmaceutical Manufacturers (AIPM) together with the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) released the findings of an analytical research on corporate healthy lifestyle practices at Russian and global companies and provide recommendations on the development and implementation of such programs. The study was prepared...
Read moreGeneva, 29 January 2014 −An independent study conducted by Charles River Associates (CRA) demonstrates that there is clear evidence that innovative medicines have delivered significant value by reducing healthcare costs and benefitting both patients and wider society. However, there remains enormous untapped potential of adopting innovative medicines more widely in middle-income countries (MICs). This can...
Read moreTrust and respect are essential for advancing healthcare Based on shared overarching principles, the Consensus Framework puts patients first, supports ethical research and innovation, ensures independence and ethical conduct, and promotes transparency and accountability Highlights best practice for different groups collaborating to advance patient healthcare Five global healthcare organizations have established a Consensus Framework for...
Read moreFake medicines put patients and the general public at risk. Patients believe they are receiving genuine treatment, but instead they are getting potentially dangerous products that could increase resistance to real treatments, and cause further illness, disability or even death. Fight the Fakes campaign (www.fightthefakes.org) will raise awareness about the dangers of fake medicines by...
Read moreIFPMA Statement at mhGAP Forum, Geneva, October 7, 2013 Delivered by Mario Ottiglio, Director, Global Health Policy & Public Affairs Thank you for the opportunity to contribute to this leading discussion today. IFPMA represents leading research-based pharmaceutical companies as well as national and regional industry associations worldwide. IFPMA highly commends the WHO Secretariat for its...
Read moreSince the MDGs’ launch, many notable health successes resulted from coordinated actions by many contributors from public and private sectors and civil society. Pharmaceutical companies lead over 220 partnerships to strengthen health systems and improve peoples’ health in low- and middle-income countries. Research-based pharmaceutical industry’s contributions to improving health demonstrate its unique role as partner...
Read moreBe He@lthy, Be Mobile is a new intersectoral initiative using mobile technology to help prevent and control NCDs. IFPMA partners to contribute knowledge and resources, lessons learned, and technical expertise to develop the best solutions for mHealth interventions for NCDs. IFPMA releases Health at your fingertips, a directory of pharmaceutical companies’ and associations’ mHealth initiatives,...
Read moreIFPMA Statement, EB 133, Item 6.2, Psoriasis Delivered by Mr Mario Ottiglio, Director, Public Affairs and Global Health Policy Thank you on behalf of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) for the opportunity to provide our perspective on psoriasis. IFPMA represents the global R&D pharmaceutical industry, whose primary contribution to global health...
Read moreWHO Executive Board, 133rd session IFPMA Statement under agenda item 5, “WHO Reform” Delivered by Mario Ottiglio, Director, Public Affairs & Global Health Policy Check against delivery, 30 May 2013 Thank you for the opportunity to contribute to this important discussion today. IFPMA represents leading research-based pharmaceutical companies as well as national and regional industry...
Read more